# EMBOLD SCLC-301 (NCT07099898)

> A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07099898
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: GlaxoSmithKline
- Conditions: Neoplasms, Lung
- Interventions: Risvutatug rezetecan (Ris-Rez); Topotecan
- Enrollment: 420
- Primary outcome: Overall Survival (OS)

## Indexed commentary on EMBOLD SCLC-301 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=embold-sclc-301-nct07099898